ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03777-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Nam-Hoon Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: TiumBio Co., Ltd. Seongnam-si, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Receptor, Transforming Growth Factor-beta Type I, Vascular Endothelial Growth Factor Receptor-2. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Transforming growth factor β (TGFβ) is present in blood of patients who do not respond to anti-programmed cell death (ligand) 1 [PD-(L)1] treatment, and through synergy with vascular endothelial growth factor (VEGF), it helps to create an environment that promotes tumor immune evasion and immune tolerance. Therefore, simultaneous inhibition of TGFβ/VEGF is more effective than targeting TGFβ alone. In this study, the dual inhibitory mechanism of TU2218 was identified through in vitro analysis mimicking the tumor microenvironment, and its antitumor effects were analyzed using mouse syngeneic tumor models. TU2218 directly restored the activity of damaged cytotoxic T lymphocytes (CTLs) and natural killer cells inhibited by TGFβ and suppressed the activity and viability of regulatory T cells. The inactivation of endothelial cells induced by VEGF stimulation was completely ameliorated by TU2218, an effect not observed with vactosertib, which inhibits only TGFβ signaling. The combination of TU2218 and anti-PD1 therapy had a significantly greater antitumor effect than either drug alone in the poorly immunogenic B16F10 syngeneic tumor model. The mechanism of tumor reduction was confirmed by flow cytometry, which showed upregulated VCAM-1 expression in vascular cells and increased influx of CD8 + CTLs into the tumor. As another strategy, combination of anti-CTLA4 therapy and TU2218 resulted in high complete regression (CR) rates in CT26 and WEHI-164 tumor models. In particular, immunological memory generated by the combination of anti-CTLA4 and TU2218 in the CT26 model prevented the development of tumors after additional tumor cell transplantation, suggesting that the TU2218-based combination has therapeutic potential in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- TiumBio Co., Ltd. Seongnam-si, Gyeonggi-do, Republic of Korea.
- TiumBio Co., Ltd. Seongnam-si, Gyeonggi-do, Republic of Korea. huntaekkim@tiumbio.com.
Zitieren
APA
Kim, N. H., Lee, J., Kim, S. H., Kang, S. H., Bae, S., Yu, C. H., Seo, J., & Kim, H. T. (2024). ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03777-4
Vancouver
Kim NH, Lee J, Kim SH, Kang SH, Bae S, Yu CH, et al. ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03777-4
BibTeX
@article{Kim2024,
author = {Kim, Nam-Hoon and Lee, Jihyun and Kim, Seung-Hyun and Kang, Seong-Ho and Bae, Sowon and Yu, Chan-Hee and Seo, Jeongmin and Kim, Hun-Taek},
title = {ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03777-4}
}
EUVIMED